NASDAQ$OTLK
Outlook Therapeutics Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Announced corporate highlights and financial results for the fiscal year ended September 30, 2020.
Outlook Therapeutics reported a net loss attributable to common stockholders of $48.9 million, or $0.67 per basic and diluted share, compared to a net loss attributable to common stockholders of $36.0 million for the prior fiscal year.
- Completed patient enrollment in its pivotal Phase 3 (NORSE TWO) clinical trial in July 2020.
- Completed enrollment of 195 subjects with a range of retinal diseases for its open-label safety study (NORSE THREE) in November 2020.
- Received agreements from the FDA on three Special Protocol Assessments (SPAs) for three additional registration clinical trials.
- Commercial launch planning for ONS-5010, including distribution, physician and patient outreach, key opinion leader support and payor community engagement, remains ongoing.
Headline financials
Revenue & EPS history
Outlook Therapeutics · Revenue · Quarterly
$127K
Forward guidance
Outlook Therapeutics is focused on completing the Phase 3 study and data readout in Q3 2021, followed by BLA submission. They are also engaged with regulatory authorities in Europe and planning registration clinical trials for DME and BRVO later in 2021.
Tailwinds
- Successful completion and data readout for the pivotal Phase 3 study in the third calendar quarter of 2021.
- Planned BLA submission.
- Engaged with regulatory authorities in Europe for anticipated submissions in those markets.
- Planning to initiate registration clinical trials for ONS-5010 for DME and BRVO later in 2021.
Headwinds
- Uncertainty of future impacts related to the ongoing COVID-19 pandemic.
- Risks associated with developing pharmaceutical product candidates.
- Risks of conducting clinical trials.
- Risks in obtaining necessary regulatory approvals.
- Risks of negotiating and finalizing binding definitive agreements with third parties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
+5.1%
Avg return
Earnings day
+6.9%
Avg return
5 days after
-0.7%
Avg return
30 days after
61%
25 / 41 earnings
Positive
+48.5%
Q2 2019
Best reaction
-14.6%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.3% | -0.9% | — | |
| Q1 2026 | -13.9% | -15.7% | -31.4% | |
| Q4 2025 | -2.9% | -11.6% | -73.6% | |
| Q3 2025 | +14.1% | +23.5% | -51.2% | |
| Q2 2025 | +1.2% | +9.9% | -0.6% | |
| Q1 2025 | +1.6% | -7.9% | -14.7% | |
| Q4 2024 | +9.4% | +11.2% | +17.1% | |
| Q3 2024 | -0.9% | -7.6% | -16.5% | |
| Q2 2024 | -0.9% | +7.4% | +3.6% | |
| Q1 2024 | +21.2% | +13.0% | +3.0% | |
| Q4 2023 | +4.2% | +8.2% | -18.5% | |
| Q3 2023 | -3.1% | -16.9% | -85.3% | |
| Q2 2023 | +3.5% | +16.5% | +46.1% | |
| Q1 2023 | -3.3% | -7.5% | -15.8% | |
| Q4 2022 | +6.9% | +4.0% | +15.8% | |
| Q3 2022 | -3.4% | +5.9% | -4.2% | |
| Q2 2022 | +7.4% | +2.7% | -37.1% | |
| Q1 2022 | +3.7% | +8.1% | +36.3% | |
| Q4 2021 | -4.2% | -1.4% | -14.6% | |
| Q3 2021 | -14.6% | -16.2% | -1.6% | |
| Q2 2021 | +16.0% | +21.2% | +34.1% | |
| Q1 2021 | -0.4% | -4.0% | -9.5% | |
| Q4 2020 | +1.3% | -4.6% | -13.1% | |
| Q3 2020 | +5.2% | +14.2% | -54.5% | |
| Q2 2020 | +1.9% | -1.9% | +40.4% | |
| Q1 2020 | +0.0% | -1.1% | -35.1% | |
| Q4 2019 | -1.7% | -53.0% | -11.1% | |
| Q3 2019 | -4.2% | -8.9% | -17.8% | |
| Q2 2019 | +48.5% | +191.3% | +125.2% | |
| Q1 2019 | +28.2% | +28.2% | -5.8% | |
| Q4 2018 | +24.5% | +42.9% | +34.7% | |
| Q3 2018 | +1.2% | -8.8% | +0.0% | |
| Q2 2018 | +2.7% | +1.1% | -13.3% | |
| Q1 2018 | +4.3% | +3.5% | -19.0% | |
| Q4 2017 | +0.0% | -7.9% | -4.8% | |
| Q3 2017 | +0.5% | +3.0% | +77.8% | |
| Q2 2017 | -8.7% | -34.1% | -24.5% | |
| Q1 2017 | +10.6% | +2.1% | -1.2% | |
| Q4 2016 | +28.6% | +40.3% | +59.8% | |
| Q2 2016 | +28.6% | +40.3% | +59.8% | |
| Q3 2016 | -3.9% | -5.3% | -8.1% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro